B-CELL MALIGNANCY
Clinical trials for B-CELL MALIGNANCY explained in plain language.
Never miss a new study
Get alerted when new B-CELL MALIGNANCY trials appear
Sign up with your email to follow new studies for B-CELL MALIGNANCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat blood cancers: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The study will enroll about 80 …
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 26, 2026 06:32 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial tests an oral drug called AS-1763 in adults with certain blood cancers (like CLL or lymphoma) that have not responded to at least two prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. Around 120 participants…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1 • Sponsor: Carna Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 06:31 UTC
-
New drug shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study is for people with B-cell blood cancers like lymphoma and leukemia. It tests a new drug, BGB-16673, that breaks down a protein helping cancer grow. The goal is to find the right dose and see if it is safe and shrinks tumors. About 146 people in China will take part.
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 26, 2026 06:26 UTC
-
CRISPR Gene-Editing takes on blood cancers in new trial
Disease control Recruiting nowThis study tests a new treatment called CTX112 for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or not responded to standard therapy. CTX112 uses CRISPR gene-editing to create donor T-cells that target and kill cancer cells. The trial involves …
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated May 26, 2026 06:24 UTC
-
New Protein-Zapper drug shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…
Matched conditions: B-CELL MALIGNANCY
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 22, 2026 14:02 UTC